Quick Answer
ORAMED PHARMACEUTICALS INC. reported Operating Income of -$15.09 million for fiscal year 2025.
ORAMED PHARMACEUTICALS INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$15.09M | -18.1% |
| 2024 | -$12.78M | +18.9% |
| 2023 | -$15.77M | +61.2% |
| 2022 | -$40.60M | -67.6% |
| 2021 | -$24.22M | -106.0% |
| 2020 | -$11.76M | +19.6% |
| 2019 | -$14.63M | -8.2% |
| 2018 | -$13.53M | -25.6% |
| 2017 | -$10.77M | -7.6% |
| 2016 | -$10.01M | -35.6% |
| 2015 | -$7.38M | -25.0% |
| 2014 | -$5.91M | -237.2% |
| 2013 | $4.30M | +249.2% |
| 2012 | -$2.88M | -18.4% |
| 2011 | -$2.44M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.43M | +21.4% | +2.5% |
| June 30, 2025 | -$2.49M | +20.6% | +44.7% |
| March 31, 2025 | -$4.50M | -51.9% | -45.7% |
| September 30, 2024 | -$3.09M | -6.8% | +1.5% |
| June 30, 2024 | -$3.13M | +17.3% | -5.8% |
| March 31, 2024 | -$2.96M | +43.1% | -2.4% |
| September 30, 2023 | -$2.89M | +64.7% | +23.7% |
| June 30, 2023 | -$3.79M | +66.8% | +27.2% |
- ORAMED PHARMACEUTICALS INC. showed a decrease of -18.1% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, ORAMED PHARMACEUTICALS INC.’s operating income has declined by 519.6% (from -$2.44 million to -$15.09 million).
- The most recent figure is from ORAMED PHARMACEUTICALS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: